

Edgar Filing: XTL BIOPHARMACEUTICALS LTD - Form 424B3

XTL BIOPHARMACEUTICALS LTD

Form 424B3

January 19, 2010

January 15, 2010

Securities & exchange Commission  
450 Fifth Street, NW  
Washington, DC 20549

Attn.: Document Control

RE: American Depositary Shares  
evidenced by the American  
Depositary Receipts each  
representing Ten (10)  
Ordinary Shares of XTL  
Biopharmaceuticals Ltd.  
(Form F-6 File No. 333-  
147677)

Ladies and Gentlemen:

Pursuant to Rule 424(b)(3) under the  
Securities Act of 1933, as amended, on  
behalf of The Bank of New York, as  
Depositary for securities against which  
American Depositary Receipts are to be  
issued, we attach a copy of the new  
prospectus (Prospectus) reflecting in number  
of ordinary shares represented by one  
American Depositary Share (the Ratio).

As required by Rule 424(e), the upper right  
hand corner of the Prospectus cover page has  
a reference to Rule 424(b)(3) and to the file  
number of the registration statement to which  
the Prospectus relates.

Pursuant to Section III B of the General  
Instructions to the Form F-6 Registration  
Statement, the Prospectus consists of the  
ADR certificate with revised ratio and par  
value for XTL Biopharmaceuticals Ltd.

The Prospectus has been revised to reflect  
the new par value and ratio, and has been  
overstamped with:

Effective June 22, 2009 the Companys  
American Depositary Share (ADS) Ratio  
Changed from 1:10 (One ADS  
Representing Ten Ordinary Shares to 1:2  
(One ADS Representing Two Ordinary  
Shares) and the Par Value Changed from  
ILS 0.02 to ILS 0.10.

Please contact me with any questions or

Edgar Filing: XTL BIOPHARMACEUTICALS LTD - Form 424B3

comments at 212 815-8223

Agness Moskovits  
Assistant Vice President  
The Bank of New York Mellon - ADR  
Division  
Encl.  
CC: Paul Dudek, Esq. (Office of International  
Corporate Finance)

101 Barclay Street, New York NY 10286